GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PCI Biotech Holding ASA (OSL:PCIB) » Definitions » EV-to-Revenue

PCI Biotech Holding ASA (OSL:PCIB) EV-to-Revenue : (As of Jun. 02, 2025)


View and export this data going back to 2008. Start your Free Trial

What is PCI Biotech Holding ASA EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, PCI Biotech Holding ASA's enterprise value is kr35.61 Mil. PCI Biotech Holding ASA's Revenue for the trailing twelve months (TTM) ended in Dec. 2024 was kr0.00 Mil. Therefore, PCI Biotech Holding ASA's EV-to-Revenue for today is .

The historical rank and industry rank for PCI Biotech Holding ASA's EV-to-Revenue or its related term are showing as below:

OSL:PCIB's EV-to-Revenue is not ranked *
in the Biotechnology industry.
Industry Median: 7.39
* Ranked among companies with meaningful EV-to-Revenue only.

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2025-06-02), PCI Biotech Holding ASA's stock price is kr1.66. PCI Biotech Holding ASA's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2024 was kr0.00. Therefore, PCI Biotech Holding ASA's PS Ratio for today is .


PCI Biotech Holding ASA EV-to-Revenue Historical Data

The historical data trend for PCI Biotech Holding ASA's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PCI Biotech Holding ASA EV-to-Revenue Chart

PCI Biotech Holding ASA Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

PCI Biotech Holding ASA Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of PCI Biotech Holding ASA's EV-to-Revenue

For the Biotechnology subindustry, PCI Biotech Holding ASA's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PCI Biotech Holding ASA's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PCI Biotech Holding ASA's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where PCI Biotech Holding ASA's EV-to-Revenue falls into.


;
;

PCI Biotech Holding ASA EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

PCI Biotech Holding ASA's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=35.605/0
=

PCI Biotech Holding ASA's current Enterprise Value is kr35.61 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. PCI Biotech Holding ASA's Revenue for the trailing twelve months (TTM) ended in Dec. 2024 was kr0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PCI Biotech Holding ASA  (OSL:PCIB) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

PCI Biotech Holding ASA's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=1.66/0
=

PCI Biotech Holding ASA's share price for today is kr1.66.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Dec. 2024 was kr0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PCI Biotech Holding ASA EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of PCI Biotech Holding ASA's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


PCI Biotech Holding ASA Business Description

Traded in Other Exchanges
Address
Ullernchausseen 64, Oslo, NOR, N-0379
PCI Biotech Holding ASA is a biopharmaceutical company focused on developing and commercializing cancer therapies using its photochemical internalization (PCI) technology platform. The PCI technology utilizes light to trigger the release of compounds from within cellular compartments. The company applies PCI to three different approaches for cancer treatment: fimaCHEM: Enhancing chemotherapeutic drugs for localized cancer treatment. fimaVACC: Inducing T-cell responses for therapeutic cancer vaccination. fimaNAc: Delivering nucleic acid therapeutics. The key product candidate is fimaporfin (Amphinex), a photosensitizer that can unlock intracellular compartments where active compounds are trapped. The company's sole operating segment is research and development.

PCI Biotech Holding ASA Headlines

No Headlines